Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence

Tools

Lancaster, Kari; Gendera, Sandra; Treloar, Carla; Rhodes, Tim; Shabazi, Jeyran; Byrne, Marianne; Nielsen, Suzanne; Degenhardt, Louisa and Farrell, Michael. 2024. Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence. International Journal of Drug Policy, 126, 104359. ISSN 0955-3959 [Article]

Preview

Text
Lancaster et al 2024 Tinkering with care IJDP.pdf - Published Version
Available under License Creative Commons Attribution.
Download (576kB) | Preview

Official URL: https://doi.org/10.1016/j.drugpo.2024.104359

Abstract or Description

We examine how extended-release buprenorphine depot (BUP-XR) is put to use and made to work in implementation practices, attending to how care practices are challenged and adapted as a long-acting technology is introduced into service in opioid agonist treatment (OAT) in Australia. Our approach is informed by ideas in science and technology studies (STS) emphasising the irreducible entanglement of care practices and technology, and in particular the concept of ‘tinkering’ as a practice of adaptation. To make our analysis, we draw on qualitative interview accounts (n = 19) of service providers involved in BUP-XR implementation across five sites. Our analysis considers the disruptive novelty of BUP-XR. Tinkering to make a novel technology work in practice slows down the expectation of implementation in relation to transformative innovation, despite the promise of dramatic or rapid change. Tinkering allowed for more open relations, for new care practices that departed from the routine and familiar, opening potential for how BUP-XR could be put to use and made to work in its new situation, and as its situation evolved along-with its implementation. Flexibility and openness of altering relations was, however, at times, held in tension with inflexibility and closure. This analysis identifies a concern for what is made present and what is made absent in the altered care network affected by BUP-XR, with the multiple effects of supervised daily dosing practices thrown into relief as they become absented. Tinkering to implement BUP-XR locally connects with a broader assemblage of trial and movement in the constitution of treatment. The introduction of long-acting technologies prompts new questions about embedded implementation practices, including supervised dosing, urinalysis, the time and place of psychosocial support, and how other social aspects of care might be recalibrated in drug treatment.

Item Type:

Article

Identification Number (DOI):

https://doi.org/10.1016/j.drugpo.2024.104359